GLUE vs MGTX: stock comparison and AI forecast
Monte Rosa Therapeutics, Inc. (GLUE) and Meiragtx Holdings Plc (MGTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GLUE Monte Rosa Therapeutics, Inc.
- Price
- $10.57 -46.6% · 6M
- Market Cap
- $902M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
MGTX Meiragtx Holdings Plc
- Price
- $8.51 -12.1% · 6M
- Market Cap
- $817M
- P/E Ratio
- 11.1x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- GLUE is 1.1 times larger than MGTX by market capitalization ($902M against $817M).
- Over the last six months MGTX returned -12.1% and GLUE -46.6%.
- MGTX turns 19.8% of its revenue into net income, against -229.2% for GLUE.
- MGTX carries 0.84 times debt per unit of equity, against 0.41 times for GLUE.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GLUE | MGTX |
|---|---|---|
| Market Cap | $902M | $817M |
| P/E Ratio | – | 11.05x |
| P/B Ratio | 1.82x | 3.79x |
| EPS | $-1.40 | $0.77 |
| Book Value/Share | $5.82 | $2.24 |
| Revenue/Share | $0.67 | $4.16 |
| FCF/Share | $-2.04 | $0.11 |
Profitability & Margins
| Metric | GLUE | MGTX |
|---|---|---|
| ROE | -26.4% | 36.6% |
| ROA | -18.8% | 19.9% |
| ROIC | -23.7% | 54.4% |
| Operating Margin | -263.9% | 46.1% |
| Net Margin | -229.2% | 19.8% |
| EBT Margin | -227.4% | 44.0% |
| Tax Rate | -0.8% | 1.3% |
Financial Health
| Metric | GLUE | MGTX |
|---|---|---|
| Current Ratio | 10.32x | 3.76x |
| D/E Ratio | 0.41x | 0.84x |
| Financial Leverage | 1.41x | 1.84x |
| Interest Coverage | – | 69.7x |
| Working Capital | $578M | $160M |
Cash Flow
| Metric | GLUE | MGTX |
|---|---|---|
| Operating Cash Flow | -$165M | $14M |
| Free Cash Flow | -$174M | $10M |
| Capital Spending | -$9M | -$3M |
| OCF Growth YoY | -210.9% | – |
| FCF Growth YoY | -220.2% | – |
| FCF/Sales | -305.2% | 2.6% |
| CapEx/Sales | 15.6% | 0.8% |
Operational Efficiency
| Metric | GLUE | MGTX |
|---|---|---|
| Asset Turnover | 0.08x | 1.01x |
| Fixed Assets Turnover | 2.0x | 4.0x |
Income Statement
| Metric | GLUE | MGTX |
|---|---|---|
| Total Revenue | $57M | $399M |
| Operating Income | -$151M | $184M |
| Net Income | -$131M | $79M |
| R&D Expense | $179M | $153M |
| SG&A Expense | – | $98M |
Dividend & Shareholder Information
| Metric | GLUE | MGTX |
|---|---|---|
| Shares Outstanding | 85M | 96M |
| Net Income Growth | -725.3% | – |
| EPS Growth | -488.9% | – |
GLUE vs MGTX: stock comparison and AI forecast
Which is bigger, GLUE or MGTX?
GLUE is 1.1 times larger than MGTX by market capitalization ($902M against $817M).
Which stock performed better over the last six months, GLUE or MGTX?
Over the last six months MGTX returned -12.1% and GLUE -46.6%.
Which one does Intratio's AI model rank higher, GLUE or MGTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.